Effects of antineoplastic and immunomodulating agents on postvaccination SARS-CoV-2 breakthrough infections, antibody response, and serological cytokine profile

• Published in: Journal for immunotherapy of cancer Vol. 12; no. 1; p. e008233
• Main Authors: New, Jacob, Cham, Jason, Smith, Lana, Puglisi, Leah, Huynh, Tridu, Kurian, Sunil, Bagsic, Samantha, Fielding, Russel, Hong, Lee, Reddy, Priya, Eum, Ki Suk, Martin, Allison, Barrick, Bethany, Marsh, Christopher, Quigley, Michael, Nicholson, Laura J, Pandey, Amitabh C
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 31.01.2024; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Original research
• Subjects: Adult; Antibody Formation; Antigens; Antineoplastic Agents; Body mass index; Bone marrow; Breakthrough Infections; Clinical/Translational Cancer Immunotherapy; COVID-19; Cytokines; Disease; Hematology; Humans; Immune Checkpoint Inhibitors; Immunogenicity, Vaccine; Immunomodulating Agents; Immunomodulation; Immunosuppressive agents; Immunotherapy; Infections; Monoclonal antibodies; Patients; Rheumatology; SARS-CoV-2; Serology; Severe acute respiratory syndrome coronavirus 2; Transplants & implants; Variance analysis; Web portals; United States > US; Massachusetts; California; COVID-19; Immunogenicity, Vaccine; Immune Checkpoint Inhibitors; Immunomodulation; Immunotherapy
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1136/jitc-2023-008233

BackgroundDespite immunization, patients on antineoplastic and immunomodulating agents have a heightened risk of COVID-19 infection. However, accurately attributing this risk to specific medications remains challenging.MethodsAn observational cohort study from December 11, 2020 to September 22, 2022, within a large healthcare system in San Diego, California, USA was designed to identify medications associated with greatest risk of postimmunization SARS-CoV-2 infection. Adults prescribed WHO Anatomical Therapeutic Chemical (ATC) classified antineoplastic and immunomodulating medications were matched (by age, sex, race, and number of immunizations) with control patients not prescribed these medications yielding a population of 26 724 patients for analysis. From this population, 218 blood samples were collected from an enrolled subset to assess serological response and cytokine profile in relation to immunization.ResultsPrescription of WHO ATC classified antineoplastic and immunomodulatory agents was associated with elevated postimmunization SARS-CoV-2 infection risk (HR 1.50, 95% CI 1.38 to 1.63). While multiple immunization doses demonstrated a decreased association with postimmunization SARS-CoV-2 infection risk, antineoplastic and immunomodulatory treated patients with four doses remained at heightened risk (HR 1.23, 95% CI 1.06 to 1.43). Risk variation was identified among medication subclasses, with PD-1/PD-L1 inhibiting monoclonal antibodies, calcineurin inhibitors, and CD20 monoclonal antibody inhibitors identified to associate with increased risk of postimmunization SARS-CoV-2 infection. Antineoplastic and immunomodulatory treated patients also displayed a reduced IgG antibody response to SARS-CoV-2 epitopes alongside a unique serum cytokine profile.ConclusionsAntineoplastic and immunomodulating medications associate with an elevated risk of postimmunization SARS-CoV-2 infection in a drug-specific manner. This comprehensive, unbiased analysis of all WHO ATC classified antineoplastic and immunomodulating medications identifies medications associated with greatest risk. These findings are crucial in guiding and refining vaccination strategies for patients prescribed these treatments, ensuring optimized protection for this susceptible population in future COVID-19 variant surges and potentially for other RNA immunization targets.